Rapamycin (Sirolimus)

Pfizer辉瑞授权 目录号:S1039 别名: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。

规格 价格 库存 购买数量  
In DMSO RMB 2501.99 现货
RMB 580.39 现货
RMB 2216.87 现货
RMB 5501.68 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献239篇:

产品安全说明书

mTOR抑制剂选择性比较

生物活性

产品描述 Rapamycin (Sirolimus)是一种特定的 mTOR 抑制剂,在 HEK293细胞中,IC50 为 ~0.1 nM。
靶点
mTOR [1]
(HEK293 cells)
~0.1 nM
体外研究

Rapamycin作用于HEK293细胞,抑制内源性mTOR活性,IC50为~0.1 nM,而iRap和AP21967 作用时,IC50分别为~5 nM 和~10 nM。[1] Rapamycin处理酿酒酵母,诱导细胞周期停在G1/S期,且抑制翻译。[2] Rapamycin显著抑制T98G和U87-MG细胞活力,这种作用具有剂量依赖性,IC50分别为2 nM和 1 μM, 而对U373-MG细胞没有作用活性,IC50>25 μM。Rapamycin(100 nM) 作用于对Rapamycin敏感的U87-MG和T98G细胞,通过抑制mTOR功能,而诱导细胞周期停在G1期,也诱导自噬而不是凋亡。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NIjXTpBEgXSxdH;4bYMhSXO|YYm= Mn;LNVAhdk1? NFnETlQ4OiCq MmqySG1UVw>? MXLQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm= Ml;6NlQ6ODB6N{O=
HT-29 NUDUOm1uS3m2b4TvfIlkKEG|c3H5 M2jxe|ExKG6P M3e4SFczKGh? NETTc25FVVOR MXvQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl? M13rUFI1QTByOEez
HT-29 MWHDfZRwfG:6aXOgRZN{[Xl? MlHONVAhdk1? NXvBOoI{PzJiaB?= NUPNdVBNTE2VTx?= MmfJVI91\W62aXH0[ZMhPS2obIXvdo92emGlaXytbY5lfWOnZDDjfZRwfG:6aXPpeJk> MXOyOFkxODh5Mx?=
PC3 NFXKRXlMcW6jc3WgRZN{[Xl? NHPIPVIyODBibl2= M3POVlEhcA>? NFm5VpBFVVOR MX3Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= M{\CelIyQTd6Nkiz
PC3 MlO0T4lv[XOnIFHzd4F6 NWPIPWJsOTByIH7N M3K2Z|EhcA>? MUfEUXNQ M1vXTWRw\XNibn;0JIlvcGmkaYSgcXRQWi2vZXTpZZRm\CCDa4SgdIhwe3Cqb4L5cIF1cW:w NWTPdmlWOjF7N{i2PFM>
PC3 MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXuxMlUh|ryP NV\rNox6OSCq NHfMXmJFVVOR MkTrTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFMzDj[YxteyC5aYToJGlEPTBib3[gQFExKG6P MUKyNVk4QDZ6Mx?=
HEK293 NVixeI1{TnWwY4Tpc44hSXO|YYm= M3LjdlExOCCwTR?= M4\DXFghcA>? NI\CO2lFVVOR NYjI[nE1UW6qaXLpeJMhXFCDLXnu[JVk\WRiZHXndoFl[XSrb36gc4YhWGSlZESge4l1cCCHQ{WwJI9nKDVyIH7N MlLxNlE2Ozl|MEG=
BT-20 M3yzRWtqdmG|ZTDBd5NigQ>? NULTPJlmOjBizszN NXvtR2dQTE2VTx?= NUK3XYw3TG:nczDuc5QhcW6qaXLpeEBuXE:UQ{Kg[IVx\W6mZX70JJBCc1RiU{S3N{BxcG:|cHjvdplt[XSrb36= M37TeFIyOzV|NUWx
U937 NHPnUZRCdnSrYnHjeIVzcWGuIFHzd4F6 MXi1NEDPxE1? NV3JfVM4PDhiaB?= NH3yfotFVVOR MXzJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? MViyNVE1OjFyNh?=
U937 MWDBcpRq[mGldHXybYFtKEG|c3H5 MV21NEDPxE1? NX3tZWp3PDhiaB?= NFfXc3NFVVOR NYqxZ5VWTG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= MnzoNlEyPDJzME[=
U937 NEXVd2FCdnSrYnHjeIVzcWGuIFHzd4F6 NEjGXno2OCEQvF2= MofNOFghcA>? M3HoXmROW09? MYHEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JGV{[2incnnjbIliKGOxbHmgTGIyODFiaX6gWVk{PyClZXzsdy=> M4HW[FIyOTR{MUC2
MCF-7 NVrSVHRWSXW2b4DoZYd6KEG|c3H5 MXuzNEBvVQ>? NEL1NHE1KGh? MWnEUXNQ NGjk[mdKdmS3Y3XzJIF2fG:yaHHnfS=> MoTFNlAxOjhzM{S=
U87MG M2faW2tqdmG|ZTDBd5NigQ>? MYixJO69VQ>? MXK2JIg> NXnEWGtyTE2VTx?= NH\xbpNRd3SnboTsfUBqdmirYnn0d{BuXE:ULX3l[IlifGWmIGO2JJBpd3OyaH;yfYxifGmxbh?= M1HVdlE6QDR6NEC0
U87MG NFfmS3pMcW6jc3WgRZN{[Xl? NVywT4o6OSEQvF2= MVe2JIg> NH\PcmtFVVOR NV3rXJRzWG:2ZX70cJkhcW6qaXLpeJMhPEWEUEGoWFcxMSCyaH;zdIhwenmuYYTpc44> NVXh[41uOTl6NEi0NFQ>
U87MG NWHVU2RXU2mwYYPlJGF{e2G7 M3nT[FEh|ryP NFXpPZQ3KGh? NUP6dG8yTE2VTx?= NYC3fYZXTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= NXf1VGtQOTl6NEi0NFQ>
U87MG M2nCWWtqdmG|ZTDBd5NigQ>? NYTKeW9nOSEQvF2= M1:4dlYhcA>? M2XjRWROW09? MW\Ec4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44> MX6xPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rheb MX;BeZRweGijZ4mgRZN{[Xl? MkGwNE4zKM7:TR?= NV;1UWlbOjRiaB?= NXPrT5R[TE2VTx?= NXqxb|J7UW6mdXPld{BifXSxcHjh[5k> NIXaeYIyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3 Ml;nRZV1d3CqYXf5JGF{e2G7 MonkNE4zKM7:TR?= NH3rRYEzPCCq MXTEUXNQ MWHJcoR2[2W|IHH1eI9xcGGpeR?= MUixPFM6OTl2OR?=
H4 M2\qS2Z2dmO2aX;uJGF{e2G7 Ml7oNE4zKM7:TR?= NF73VIQzPCCq NV3udGQxTE2VTx?= NELzW2RKdmO{ZXHz[ZMhfGinIILheIlwKG:oIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAzKHSxIHzp[4h1KGOqYXnuJFMhe3WkdX7peEAyKGmwIHj1cYFvKEh2IHPlcIx{ NWTJb2ExOThyMkS1PFQ>
HeLa MYnGeY5kfGmxbjDBd5NigQ>? NXrWWYVMOTByIH7N NVHLTGJUOzZiaB?= NFTad4hFVVOR NXjsfHZFUW6mdXPld{BHWkJiS{KwPVVRNCCWMkC5PGwtKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>? NVPPZ|FWOTd3NkOzPFU>
HeLa NWjNbnQ6TnWwY4Tpc44hSXO|YYm= M4nGPVExOCCwTR?= M2jQNVM3KGh? M1jYcWROW09? Ml\pTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v M3P4eVE4PTZ|M{i1
HeLa MX7GeY5kfGmxbjDBd5NigQ>? NHTUTW0yODBibl2= Mnz0N|YhcA>? M2CxfGROW09? NFPLboRKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> NVf5Z49jOTd3NkOzPFU>
SYF M{\MW2Z2dmO2aX;uJGF{e2G7 M2PhbFExOCCwTR?= Mo\ZNlQhcA>? NU\BeYNtTE2VTx?= NF;tOXNKdmS3Y3XzJGZTSi2IS1LQJINwdXCuZYigbY51\XKjY4Tpc44> MojXNVc2PjN|OEW=
SYF NETWZVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonFNVAxKG6P NHTJfmQzPCCq MYnEUXNQ MomzTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IGPZSkBk\Wyucx?= MV:xO|U3OzN6NR?=
HEK293T MXfBcpRqfmm{YXygRZN{[Xl? M{i5dlEhdk1? MWW0JIQ> M4rIbWROW09? M4jkfmlv\HWlZYOgZY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgTGlXOSCUNTD3bZRpKEWFNUCgc4YhOC5zIH7N M{G0SVE4PDh3NUCx
HEK293T M1jNWmFvfGm4aYLhcEBCe3OjeR?= MYWxJI5O NHuwNZg1KGR? M2Kwb2ROW09? MlnkTY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= NHnpRWgyPzR6NUWwNS=>
PBMC NULlcHRPTnWwY4Tpc44hSXO|YYm= MnfRNUBvVQ>? MYixOEBl MVHEUXNQ MXnS[YR2[2W|IFPDVlUh\GWwc3n0fS=> M3jnd|E4PDh3NUCx
PBMC NVrCWldSTnWwY4Tpc44hSXO|YYm= Mo\HNUBvVQ>? NHTK[GoyPCCm MYfEUXNQ MUDEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=> MoDCNVc1QDV3MEG=
HEK293 cells M4\YfWtqdmG|ZTDBd5NigQ>? NYW1fpZJPTBibl2= Mn;DOFUhdWmw M4m1UmROW09? Moi0TY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? MlHBNVc{PTB7NUO=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc MXPGeY5kfGmxbjDBd5NigQ>? MUmxNFAhdk1? MkO5OEBp NVvVXWFOTE2VTx?= NWHucXNVUW6mdXPld{BtfWOrZnXyZZNmKHC{b4TlbY4hfHKjboOtd5BtcWOrbnegbY4hTHKxc3;wbIlt[SCvZXzhco9o[XO2ZYKgV|Ih[2WubIOgeJJidnOoZXP0[YQhf2m2aDDOMYx2[yCjbnSgR{1tfWN? NFLCXYcyPzF{OEK2Ni=>
Human mixed lymphocyte MnrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MluwOUBvVQ>? MX3EUXNQ M3rHOmlEPTB;MT62JI5ONg>? MWqxOlE5PTh4NR?=
Lewis rat lymph node cells NVPJepdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;0TFg2KM7:TR?= NVm0OHpUTE2VTx?= NYDxZ2lCUUN3ME2yMlYh|ryP M2LOSVE3OTh3OE[1
cells from the thymus of normal BALB/c mice MoLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\jVJBMOTBibl2= NVSwTYVZPzJiaB?= Mn;4SG1UVw>? M3fIN2lvcGmkaYTzJIx6dXCqb4Dyc4xq\mW{YYTpc44hMEyDRjmge4l1cCCLQ{WwJI9nKDNibl2= MmHvNVAxOjF7NEi=
MRK-nu-1 NI\hZ3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTBwOES1JJBO NEfMZYpUSU6JRWK=
OCUB-M Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEO1N|NKSzVyPUWuNlQheE1? NGHuVIxUSU6JRWK=
SF539 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXq0[VJiUUN3ME2xNU43KHCP M4LZWHNCVkeHUh?=
ES4 NEDJWXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1y0XWlEPTB;MkGuOUBxVQ>? MlfrV2FPT0WU
RL95-2 Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\GOYh{UUN3ME2xNFcheE1? M3nkeXNCVkeHUh?=
LC-2-ad Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq5N5NrUUN3ME20NlMheE1? MWHTRW5ITVJ?
Daudi MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXYTWM2OD12M{SgdG0> MULTRW5ITVJ?
NTERA-S-cl-D1 NFnJcllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnMWVJKSzVyPUS0N{BxVQ>? MljxV2FPT0WU
OS-RC-2 Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTZ3MjDwUS=> MWHTRW5ITVJ?
VA-ES-BJ NWizW4tGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTd{MzDwUS=> NUD2WmxIW0GQR1XS
GR-ST MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTh2NjDwUS=> M4e3fnNCVkeHUh?=
SW872 NUP6XJl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TSWmlEPTB;OES2JJBO MWHTRW5ITVJ?
NOS-1 M1fXOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzOZ5FKSzVyPUi3NUBxVQ>? Ml3kV2FPT0WU
MC116 M4\kNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmD6TWM2OD17OEWgdG0> M17VOHNCVkeHUh?=
NCI-H1355 NGnLVmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXuSHZKSzVyPUGuNFEhdk1? NIDBPJZUSU6JRWK=
RPMI-8226 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nQUmlEPTB;MT6xPUBvVQ>? MUTTRW5ITVJ?
TE-15 NFTPNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jCPWlEPTB;MT6zOkBvVQ>? Mn74V2FPT0WU
Ramos-2G6-4C10 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS4SVllUUN3ME2xMlQ3KG6P NX7uVHo3W0GQR1XS
KU812 M2fIO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTJwMEGgcm0> Mn;ZV2FPT0WU
EW-1 MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfsTWM2OD1{LkG3JI5O MkPMV2FPT0WU
KS-1 MmqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkH6TWM2OD1{LkS1JI5O M3j3NXNCVkeHUh?=
SK-LMS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\Me2lEPTB;Mj60PUBvVQ>? NFK1TYVUSU6JRWK=
TGBC1TKB MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfOdlZKSzVyPUKuOlkhdk1? M32wO3NCVkeHUh?=
TE-6 NWrh[4tpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTJwN{egcm0> M2WzfHNCVkeHUh?=
ETK-1 NH:1U4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIW3fHFKSzVyPUKuPFIhdk1? NH3EVlJUSU6JRWK=
BE-13 MmGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1THU2lEPTB;Mj65PUBvVQ>? M2Pw[nNCVkeHUh?=
A3-KAW NVS3WXY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJwOUmgcm0> MonxV2FPT0WU
TE-10 NGnmTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPJXlRKSzVyPUOuN{BvVQ>? NGHScYxUSU6JRWK=
DOHH-2 NXziSVVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTNwM{Wgcm0> MnrSV2FPT0WU
ES6 MmTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETmPG9KSzVyPUOuOFMhdk1? M1LqfnNCVkeHUh?=
OPM-2 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[4T2lEPTB;ND6xOUBvVQ>? NFe0fI9USU6JRWK=
SH-4 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX1elBmUUN3ME20MlM1KG6P M{fNdnNCVkeHUh?=
NB13 Mm[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL1c3ZKSzVyPUSuN|Yhdk1? NXLSW5k{W0GQR1XS
HUTU-80 M1rEcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\pW2s4UUN3ME20MlQzKG6P NEjxNIJUSU6JRWK=
CCRF-CEM M1jxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWq5flQ1UUN3ME20Mlk1KG6P MnLCV2FPT0WU
TGBC24TKB MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PzSmlEPTB;NT61NUBvVQ>? Ml\wV2FPT0WU
697 MnvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzld5NSUUN3ME22MlI5KG6P NHX1T3NUSU6JRWK=
J-RT3-T3-5 NWP3dpRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTZwNE[gcm0> M{C5W3NCVkeHUh?=
KALS-1 NGC1c4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTTJZKSzVyPU[uOVYhdk1? MX\TRW5ITVJ?
no-10 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TQPWlEPTB;Nz6yPUBvVQ>? NYD1fm9qW0GQR1XS
SK-NEP-1 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYK4b2N2UUN3ME24Mlc6KG6P M1rBVXNCVkeHUh?=
L-540 M33lVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFyLkSyJI5O NVntVXF2W0GQR1XS
JiyoyeP-2003 NXrWbpR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPIOIlKSzVyPUGwMlk1KG6P M2TjeXNCVkeHUh?=
HH NY\ZUWozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;Be2lEPTB;MUGuN|khdk1? NV;ITVNJW0GQR1XS
SR M1ntcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGxcFlKSzVyPUGxMlQ2KG6P NI\qNFNUSU6JRWK=
QIMR-WIL MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7kdYllUUN3ME2xNU45PSCwTR?= MkHMV2FPT0WU
A4-Fuk NHrhO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHJTWM2OD1zMz6xNkBvVQ>? NWfUZ4YyW0GQR1XS
CESS MkDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF|LkGzJI5O NYe1XHBJW0GQR1XS
KE-37 M{Plc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUX2bpd1UUN3ME2xOk4xPyCwTR?= MYLTRW5ITVJ?
SK-UT-1 Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTF4LkixJI5O NYHNc5NFW0GQR1XS
SIG-M5 M2fqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUf2N4NvUUN3ME2xO{4zPSCwTR?= Mn[5V2FPT0WU
HT MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HDU2lEPTB;MUeuOkBvVQ>? MUHTRW5ITVJ?
DEL NEHwe2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF5Lkm5JI5O MYLTRW5ITVJ?
SK-PN-DW NYqwZZlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLteFBYUUN3ME2yNE4zOyCwTR?= NYrQSZBlW0GQR1XS
RPMI-8402 NYnBZmNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXkNld2UUN3ME2yNU44PyCwTR?= NWLWdJVLW0GQR1XS
RPMI-6666 NYm0bXg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonTTWM2OD1{ND60NkBvVQ>? MmfOV2FPT0WU
NCI-H720 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTJ3LkSxJI5O MnTDV2FPT0WU
EW-16 MnXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPXSmpWUUN3ME2yOk45PyCwTR?= MonTV2FPT0WU
BL-70 Mny3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrRdJR[UUN3ME2yPE4{QCCwTR?= MX\TRW5ITVJ?
SF126 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXHSmpzUUN3ME2zNE4{QCCwTR?= NUHz[VAyW0GQR1XS
BC-1 NVTUfnBMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTNzLkK2JI5O MmDTV2FPT0WU
MHH-PREB-1 NWHsV|FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF3RZ3pKSzVyPUOyMlQ1KG6P Mmi0V2FPT0WU
A101D MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTN{Lk[yJI5O MVTTRW5ITVJ?
NMC-G1 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\nTWM2OD1|Mz62O{BvVQ>? Mmm2V2FPT0WU
LB1047-RCC M360RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nOWmlEPTB;M{SuOlkhdk1? NXjnUmlNW0GQR1XS
EM-2 NHPIVXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmX0TWM2OD1|OD61N{BvVQ>? MmXyV2FPT0WU
COLO-684 M2rsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIT3WHBKSzVyPUO5Mlghdk1? MYrTRW5ITVJ?
Becker M1PRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TxXmlEPTB;NEGuNFUhdk1? M3\IfXNCVkeHUh?=
BL-41 MnT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPJZXZKSzVyPUSzMlY3KG6P M4fEeHNCVkeHUh?=
MDA-MB-134-VI NV;tZW5rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nZO2lEPTB;NESuNFIhdk1? MnvuV2FPT0WU
L-363 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDhTWM2OD12ND63N{BvVQ>? NX3ETYVnW0GQR1XS
ECC4 NWPE[YRzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv1fGdOUUN3ME20OE44QCCwTR?= MVHTRW5ITVJ?
A388 MmW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17GNGlEPTB;NESuPFIhdk1? M3;3eHNCVkeHUh?=
HEL M17rOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;BNlNKSzVyPUS5Mlc6KG6P NWLkfnZzW0GQR1XS
RKO NGi1[mtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTVyLkK5JI5O NH3Ce2tUSU6JRWK=
KINGS-1 M3nPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf4XXpKSzVyPUWxMlU2KG6P M1PVe3NCVkeHUh?=
EB-3 M3rkb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjZWXVrUUN3ME21Nk43PyCwTR?= M1H6OnNCVkeHUh?=
ARH-77 M1HDRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHHT3h[UUN3ME21Nk45KG6P MYXTRW5ITVJ?
GCIY MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LDNmlEPTB;NUOuOFYhdk1? M37iT3NCVkeHUh?=
NCI-H1304 Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HJVWlEPTB;NUeuNlIhdk1? M324WnNCVkeHUh?=
KARPAS-299 NXi4XpZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LrdmlEPTB;NkGuPFIhdk1? MnvEV2FPT0WU
IA-LM M1PGXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTqTWM2OD14OD6xN{BvVQ>? M1L6UXNCVkeHUh?=
GI-1 NUfweXl3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe3Xop3UUN3ME23NE4{QSCwTR?= NVzN[ZBNW0GQR1XS
TE-11 NIHaZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfHemNKSzVyPUe3MlE4KG6P M33STXNCVkeHUh?=
LS-411N NHj1RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7OblJZUUN3ME23O{42PyCwTR?= M3nJRXNCVkeHUh?=
no-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTh|LkK0JI5O M3nqXnNCVkeHUh?=
MV-4-11 NX7RdWdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3HTWM2OD16Mz63N{BvVQ>? NGD5N5NUSU6JRWK=
BV-173 NHnaSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTh|Lkm3JI5O MYrTRW5ITVJ?
CMK NG\wb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7lSlJKSzVyPUi0MlE3KG6P NHHS[FJUSU6JRWK=
LC4-1 NVXRb2lIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:yTGlEPTB;OE[uO|Ihdk1? Mnj1V2FPT0WU
COR-L279 Mn6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NISwUXNKSzVyPUi3MlI2KG6P MmPCV2FPT0WU
NCI-H209 MnLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUHJR|UxRTh5LkSxJI5O NHv5ZWZUSU6JRWK=
Raji MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4Hi[WlEPTB;OEmuO|Ihdk1? NEm5UWhUSU6JRWK=
LB996-RCC MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTVd5VQUUN3ME25N{41OyCwTR?= MWrTRW5ITVJ?
NCI-H526 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTl|LkW5JI5O M3fMfXNCVkeHUh?=
KGN M4[ydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTGTWM2OD17Nj6yPUBvVQ>? MU\TRW5ITVJ?
MOLT-4 NXLnPWo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nrXmlEPTB;OU[uO|khdk1? NV\XOodOW0GQR1XS
PF-382 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTIbGZUUUN3ME25Ok44QSCwTR?= M{XPWHNCVkeHUh?=
BC-3 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX33VIppUUN3ME25PU4yQCCwTR?= Mkn1V2FPT0WU
KARPAS-422 NXTjVnQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlOzTWM2OD1zMEKuNFkhdk1? MXvTRW5ITVJ?
SBC-1 NYO2VmR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFThTYtKSzVyPUGwO{44PSCwTR?= MYfTRW5ITVJ?
LC-1F MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTFyOD6wOUBvVQ>? M4iwenNCVkeHUh?=
GB-1 MmH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXrqZmI4UUN3ME2xNFkvODJibl2= MnTZV2FPT0WU
SNB75 M17SNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnYRXZKSzVyPUGxPU43QSCwTR?= M4Ln[3NCVkeHUh?=
BB65-RCC NIj6Z|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rWS2lEPTB;MUG5Mlk{KG6P Moe0V2FPT0WU
NCI-N87 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF{MT65PEBvVQ>? MWTTRW5ITVJ?
IST-MEL1 M4\2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7DTWM2OD1zMkKuN|ghdk1? M4q2[XNCVkeHUh?=
HOP-62 NF76[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\ncmlGUUN3ME2xNlYvQDlibl2= MY\TRW5ITVJ?
ACN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjCeZRWUUN3ME2xOFYvPzVibl2= NIewPIpUSU6JRWK=
DMS-114 M{TXNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrsdYsxUUN3ME2xOVAvPjdibl2= MUPTRW5ITVJ?
MLMA NYqxN|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjDenJKSzVyPUG1PU45QCCwTR?= MkP3V2FPT0WU
HT-144 M4rPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorjTWM2OD1zNkWuOFMhdk1? NGDrUGZUSU6JRWK=
C2BBe1 NVv3VGVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVr2Z5ZJUUN3ME2xOlcvPzZibl2= NVz1d5V{W0GQR1XS
L-428 Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTF5Nz63JI5O MnThV2FPT0WU
DU-4475 NXTDPXJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLyTWM2OD1zOEeuOlghdk1? MnfrV2FPT0WU
CP67-MEL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjMOGpKSzVyPUG5PU4{QCCwTR?= MlLWV2FPT0WU
MEG-01 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD5W2dRUUN3ME2yNFEvQTZibl2= MljnV2FPT0WU
IST-SL2 MmXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:0cm5KSzVyPUKwPE43OyCwTR?= MYnTRW5ITVJ?
ES8 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfmPVhKSzVyPUKyOU46PCCwTR?= M{jmOXNCVkeHUh?=
COLO-800 M3X1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jjVWlEPTB;MkO1MlI5KG6P NWP2OZdVW0GQR1XS
MFH-ino M1rXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrhN3VKSzVyPUKzOU45PCCwTR?= M4rsRnNCVkeHUh?=
OVCAR-4 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXWVW5KSzVyPUKzO{4zPCCwTR?= MVzTRW5ITVJ?
PSN1 NIXsNnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJ2Mj63NUBvVQ>? NUj1d3dKW0GQR1XS
EW-12 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH0TWM2OD1{NEOuNUBvVQ>? NV7n[XlCW0GQR1XS
HCC1599 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJ4MT60O{BvVQ>? NGrU[pJUSU6JRWK=
SJSA-1 NWXifpl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHwXlVKSzVyPUK3NU41PiCwTR?= MlXtV2FPT0WU
ST486 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYPFfZBsUUN3ME2yPVYvOTRibl2= Ml\jV2FPT0WU
NOMO-1 NW\wdndPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLKTWM2OD1|MECuNlEhdk1? NH\JbolUSU6JRWK=
MN-60 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TzW2lEPTB;M{C1MlMzKG6P M2DvfXNCVkeHUh?=
HCC1187 M17YS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTNyNz6yOUBvVQ>? MUnTRW5ITVJ?
SW982 M3S0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTNzND63OUBvVQ>? MVnTRW5ITVJ?
LB647-SCLC NHvUPFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLQO|FXUUN3ME2zNlgvPzFibl2= NYDBO3ZRW0GQR1XS
HC-1 M3ToU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnGTWM2OD1|M{WuOUBvVQ>? NV;xXnFMW0GQR1XS
EHEB M1HHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTN|Nz61NkBvVQ>? M2LiPXNCVkeHUh?=
TUR NHXw[FNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fqTmlEPTB;M{[zMlk2KG6P NID0TFlUSU6JRWK=
LU-139 M1HsZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPpVHVYUUN3ME2zO|gvODJibl2= M2XUcXNCVkeHUh?=
NB1 NELWVZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13WcmlEPTB;M{i0MlQ2KG6P MoPxV2FPT0WU
BB30-HNC NXfCVmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHpTWM2OD1|OEiuN|Ihdk1? MYrTRW5ITVJ?
HAL-01 NYfFUJE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTN6OT6yOkBvVQ>? MoqyV2FPT0WU
K5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLkcFdKSzVyPUSxNU4{PyCwTR?= MVnTRW5ITVJ?
MZ2-MEL NFPKSWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvVSnZLUUN3ME20NVMvPjRibl2= MX7TRW5ITVJ?
RXF393 MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLWTWM2OD12MU[uOFUhdk1? NFLwTVNUSU6JRWK=
NCI-H1648 NUXadYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HveGlEPTB;NEG3MlU{KG6P NET4UXFUSU6JRWK=
TE-12 M4e4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIe3N2FKSzVyPUSzOE4zPiCwTR?= M3HYPHNCVkeHUh?=
EoL-1- MnjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHKweFNKSzVyPUSzO{46QCCwTR?= M3HUR3NCVkeHUh?=
JAR NGTGcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTR|OD62NkBvVQ>? NFXYcJhUSU6JRWK=
DSH1 MlLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;zTWM2OD12NUiuPVEhdk1? NVzMNpF7W0GQR1XS
NCI-H187 NYrYW4w{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUK2VZRDUUN3ME20OlIvQDFibl2= M3TJR3NCVkeHUh?=
HCE-4 MmXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnUTWM2OD12N{euOlYhdk1? MYTTRW5ITVJ?
8-MG-BA MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\xbGlEPTB;NUixMlUzKG6P NWrpdWtTW0GQR1XS
KLE M{PPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS5TWM2OD13OEWuNkBvVQ>? MXLTRW5ITVJ?
KNS-42 M1zD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjGRm9KSzVyPUW4Ok45OSCwTR?= MkHRV2FPT0WU
MSTO-211H M3W2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjicIJKSzVyPU[wPU44PCCwTR?= NEXiRYVUSU6JRWK=
GDM-1 MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZzND6wPUBvVQ>? MUjTRW5ITVJ?
TE-1 MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HiPGlEPTB;NkS2MlEzKG6P MUPTRW5ITVJ?
BT-474 NGPiNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\t[nlKSzVyPU[0O{4xPiCwTR?= NHHwS5hUSU6JRWK=
KARPAS-45 NHTIZlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr3dYtKSzVyPU[0O{43KG6P NF\ZRnVUSU6JRWK=
MOLT-16 M{C3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjpV5BsUUN3ME22OFcvQTNibl2= NFHlVlFUSU6JRWK=
KURAMOCHI MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLacHN6UUN3ME22OVcvPTFibl2= NXTJN3BxW0GQR1XS
K-562 NU\KPHVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS1TWM2OD14NkmuOVEhdk1? M1\VXXNCVkeHUh?=
EKVX NE\lR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTZ5Mj63NUBvVQ>? MWDTRW5ITVJ?
GAK M4Cwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDmTWM2OD14N{WuN{BvVQ>? M1\5R3NCVkeHUh?=
NCI-SNU-5 NHzH[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7o[29KSzVyPU[5NE4xOSCwTR?= MoDHV2FPT0WU
NCI-H2126 NXfnb457T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn3V5BlUUN3ME23NlYvQDdibl2= MVPTRW5ITVJ?
CTV-1 Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrTSlUxUUN3ME23OFQvQSCwTR?= M1HXfHNCVkeHUh?=
SW962 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYSwdG0yUUN3ME23OFgvPDRibl2= NWSzTXpDW0GQR1XS
MONO-MAC-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnMXo5UUUN3ME23OVYvQTNibl2= M4O3[XNCVkeHUh?=
NCI-H748 M4fCSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGOFZmUUN3ME23OVgvQTlibl2= MVPTRW5ITVJ?
NCI-H524 Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfFWpRKSzVyPUe4NE44OyCwTR?= MVXTRW5ITVJ?
LS-123 M{fVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO0dIdEUUN3ME23PVUvPjlibl2= NVnyT4FYW0GQR1XS
NB7 MomyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzBSIdKSzVyPUixOE4yPCCwTR?= MkPhV2FPT0WU
LS-1034 M1;Ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\GTWM2OD16MkiuPVghdk1? NHTkWIlUSU6JRWK=
TE-5 M1L0R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTh6Mz61OkBvVQ>? M1K5[nNCVkeHUh?=
A704 M2nkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nyVmlEPTB;OEm5MlE2KG6P M{nsbHNCVkeHUh?=
TK10 M2O2OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe1[2RKSzVyPUmxOk4xOyCwTR?= NYLpNoZuW0GQR1XS
NCI-H345 MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHrH[JhKSzVyPUm0N{4zOiCwTR?= NH6xUnZUSU6JRWK=
CGTH-W-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYH6R|RPUUN3ME25OFgvOTNibl2= NVu5bHprW0GQR1XS
NCI-H510A MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;RTWM2OD17OEWuNVIhdk1? NVHjW3FjW0GQR1XS
NCI-H1963 NY\4PGt6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fCZ2lEPTB;MT6wN|I6OiEQvF2= M4DO[nNCVkeHUh?=
SCC-3 NG\4TJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33VeGlEPTB;MT6wN|QyPCEQvF2= NYizbIFWW0GQR1XS
EW-11 NHXDUmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q1cWlEPTB;MT6wPFc1OyEQvF2= NXPsZpBqW0GQR1XS
CPC-N NULOO3JjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nTfmlEPTB;MT6wPFgh|ryP NFzQXXBUSU6JRWK=
NCI-H1417 NV7DcFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjPTWM2OD1zLkGyNlYh|ryP MmHpV2FPT0WU
DG-75 NWO1XotzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjKbGtKSzVyPUGuNVYzQDVizszN MkDvV2FPT0WU
HD-MY-Z NVLJO3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTFwMU[0NVYh|ryP M3rTOnNCVkeHUh?=
ATN-1 M2TmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHQTWM2OD1zLkK2NlA6KM7:TR?= NUS0TYRjW0GQR1XS
KM-H2 M3qyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe2fpdKSzVyPUGuNlY1ODhizszN NXm3NWFSW0GQR1XS
NCI-H2081 NXnLfIJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjRd2NSUUN3ME2xMlI3PjN5IN88US=> NXi1VI5JW0GQR1XS
HL-60 M3PQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrmRlg3UUN3ME2xMlI3QTV7IN88US=> NHW4fI1USU6JRWK=
DB NFK2VppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NECxO3FKSzVyPUGuNlczPDJizszN NUDSV4JmW0GQR1XS
NCI-H1522 NI[wSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzPTWM2OD1zLkK4PFg4KM7:TR?= NHjWWYtUSU6JRWK=
AM-38 NWfwV5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHv5VJlKSzVyPUGuN|A4OiEQvF2= MYTTRW5ITVJ?
NCI-H446 NFHzemZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPEW5VKSzVyPUGuN|IyOjFizszN M2TFTXNCVkeHUh?=
SU-DHL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLKdoFKSzVyPUGuN|I5ODFizszN Mmr1V2FPT0WU
NH-12 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFwM{[zO|Qh|ryP NYHrWoFZW0GQR1XS
DMS-79 MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TGPGlEPTB;MT6zOlg3PiEQvF2= NIDFdINUSU6JRWK=
NCI-H716 MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLVVWFKSzVyPUGuN|g6QDZizszN NHLx[m9USU6JRWK=
ML-2 MoPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojGTWM2OD1zLkSxOVI6KM7:TR?= MVXTRW5ITVJ?
NB10 NWTDT2NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1L1OWlEPTB;MT60OlY{OiEQvF2= NWTTSGZCW0GQR1XS
ONS-76 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTFwNUO1Olkh|ryP NET3N|lUSU6JRWK=
LOUCY M2LweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrzNnU1UUN3ME2xMlU1PjV5IN88US=> NXP3SGFTW0GQR1XS
SCLC-21H NInoeIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\BeWZKSzVyPUGuOVg2QDJizszN MX\TRW5ITVJ?
TGW MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{H5T2lEPTB;MT62N|k4PSEQvF2= MUHTRW5ITVJ?
LXF-289 M3noe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnQ[YhGUUN3ME2xMlc{OjZ6IN88US=> NWf2dopUW0GQR1XS
BB49-HNC NGDPeVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXXTWM2OD1zLkezOVg3KM7:TR?= NF;ibXFUSU6JRWK=
NCI-H747 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTFwN{WzOFYh|ryP NFnuZoZUSU6JRWK=
LU-165 NYnud4tFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm2eIZ6UUN3ME2xMlg1QTh4IN88US=> MVjTRW5ITVJ?
OMC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\NTWM2OD1zLkm1NFY3KM7:TR?= NFzRNFlUSU6JRWK=
RCC10RGB NV[0VZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1XlVWlEPTB;MT65OVgyPyEQvF2= MVTTRW5ITVJ?
SW684 NHy2R4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXYZ5RKSzVyPUGuPVYxQTlizszN MYfTRW5ITVJ?
TE-8 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTJwMEW1OVkh|ryP MWTTRW5ITVJ?
SK-N-DZ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTPd4ZsUUN3ME2yMlE{Ojd2IN88US=> MWDTRW5ITVJ?
EVSA-T MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XTPGlEPTB;Mj6xO|MyPSEQvF2= NITSWZBUSU6JRWK=
KASUMI-1 M3LRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHD[HZzUUN3ME2yMlE5QDF3IN88US=> MYPTRW5ITVJ?
NKM-1 NHzOSmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLvTWM2OD1{LkK1OFczKM7:TR?= MlPTV2FPT0WU
CAL-148 NEO1SGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoC2TWM2OD1{LkOzOlE1KM7:TR?= MknDV2FPT0WU
NCI-H64 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nST2lEPTB;Mj6zOFI{OiEQvF2= NHO2ZVdUSU6JRWK=
KNS-81-FD NWjRbmRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LV[2lEPTB;Mj6zOlYzKM7:TR?= M3eyV3NCVkeHUh?=
KM12 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwNEC4N|kh|ryP Mm\YV2FPT0WU
SW954 MlPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\wd3lbUUN3ME2yMlQ4Pzd7IN88US=> NWfYd4xEW0GQR1XS
NCI-H1395 M4nMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\tTWM2OD1{LkWyOlQ2KM7:TR?= NF\VZmdUSU6JRWK=
DJM-1 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYriWndjUUN3ME2yMlYxPjNizszN NEG3eHRUSU6JRWK=
COLO-668 NFfTUYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;WTWM2OD1{LkiyOlk2KM7:TR?= MlvLV2FPT0WU
NCI-H1436 NFTwcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJwOEW2NVUh|ryP MnvsV2FPT0WU
LB2241-RCC MnjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PzSGlEPTB;Mj64Olg{QSEQvF2= MlvMV2FPT0WU
GT3TKB NWXnc2x7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL2SJFKSzVyPUKuPFkxPTVizszN MkDNV2FPT0WU
COLO-824 NWj2c4dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvJRodJUUN3ME2yMlg6PzZ6IN88US=> MUfTRW5ITVJ?
ES1 M2\ObGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETacVhKSzVyPUKuPFk5PzlizszN NH25UWRUSU6JRWK=
LB771-HNC NVj6UGtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD4TWM2OD1{LkmwPVQ3KM7:TR?= NETjc3RUSU6JRWK=
GI-ME-N NFL0SmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDxPFFKSzVyPUOuNFA6ODRizszN Ml6wV2FPT0WU
NALM-6 NGPJXFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXz6UJpwUUN3ME2zMlAxQTN|IN88US=> NUXBO243W0GQR1XS
LU-134-A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWewRpVJUUN3ME2zMlA2PDJ3IN88US=> M1fFUHNCVkeHUh?=
DMS-153 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTNwMEW4NlQh|ryP NWX2cJNxW0GQR1XS
MZ1-PC NIPhVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTNwMEmwO|gh|ryP MX7TRW5ITVJ?
NCI-H1155 Mlf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYW3UIJiUUN3ME2zMlEyPjFizszN NIC3[olUSU6JRWK=
CAS-1 M1PuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnznTWM2OD1|LkGzO|A4KM7:TR?= M1rzWXNCVkeHUh?=
D-502MG NIL1eIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoCxTWM2OD1|LkG0N|kh|ryP MnT4V2FPT0WU
NCI-H2141 MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnn2TWM2OD1|LkG3OFUzKM7:TR?= M2W1THNCVkeHUh?=
NB6 NWXjS3dOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjldFFoUUN3ME2zMlE5OjV7IN88US=> NXjlWGk1W0GQR1XS
NCCIT M4j6eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT5T4ZKSzVyPUOuNlE5ODlizszN NGnSemdUSU6JRWK=
NB69 M{DwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPoT|hKSzVyPUOuN|E5QTFizszN MUnTRW5ITVJ?
JVM-2 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTNwM{[0N|Mh|ryP MoS5V2FPT0WU
K052 M4DFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Dq[WlEPTB;Mz6zO|k3QCEQvF2= NUDa[4N[W0GQR1XS
HCC2157 NUTn[ZN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfPTWM2OD1|LkWzNlI5KM7:TR?= NWHLSWQ4W0GQR1XS
KMOE-2 NFPwcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTNwNUSyOFIh|ryP NFHhOJFUSU6JRWK=
SF268 NYq2XlVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwN{G1OVQh|ryP NWrkelJtW0GQR1XS
CHP-126 NEHmV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL4TWM2OD1|Lke2OFU5KM7:TR?= MWHTRW5ITVJ?
CP66-MEL NUjnZXg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3OWJhKSzVyPUOuO|kxQTRizszN MkLFV2FPT0WU
NCI-H69 NFy2fmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXGNmlKSzVyPUSuNFE6OzZizszN NIPnR5RUSU6JRWK=
A253 MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrOOG1nUUN3ME20MlAzOTBzIN88US=> M1jtPHNCVkeHUh?=
NB14 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwMUC0O|kh|ryP M3jYUXNCVkeHUh?=
NCI-H1694 MluyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTRwMUOxNVIh|ryP NHG4dm1USU6JRWK=
NCI-H2196 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nkT2lEPTB;ND6xO|E3QSEQvF2= MkK4V2FPT0WU
TE-9 NEnKc4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\OTWM2OD12LkG3OVgzKM7:TR?= M3\HbXNCVkeHUh?=
D-283MED NHHDPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTRwMUi4OEDPxE1? M2r2XnNCVkeHUh?=
OCI-AML2 Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPHTWM2OD12LkG5OFg6KM7:TR?= M4nsc3NCVkeHUh?=
D-263MG NFLnO|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwMkK5OlEh|ryP NWfMN25XW0GQR1XS
MPP-89 NVjNZ|VMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLZ[WNrUUN3ME20MlI4OzB2IN88US=> NVnkcIhOW0GQR1XS
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTRwM{C0NlEh|ryP NGSwcW9USU6JRWK=
LB373-MEL-D NIfHRWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX72e2RLUUN3ME20MlM3Pzh7IN88US=> M2rMZnNCVkeHUh?=
UACC-257 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTRwM{m1N|Qh|ryP NFPZeHhUSU6JRWK=
MC-CAR NUP4eVI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7GRpFKSzVyPUSuOFM6QSEQvF2= NUX6[oZHW0GQR1XS
COLO-320-HSR NUTMRogyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRwNES0Nlch|ryP NFjocoxUSU6JRWK=
P30-OHK NILwTopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvYSnZKSzVyPUSuOlY2QDFizszN MYLTRW5ITVJ?
UACC-812 MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH5RolKSzVyPUSuOlkyPjFizszN NEDYc2tUSU6JRWK=
CTB-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwN{G1OVUh|ryP NIezSJJUSU6JRWK=
ALL-PO M3\nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPrTWM2OD12Lki0NFc4KM7:TR?= NWLwbGV7W0GQR1XS
SK-MEL-2 NUezbFhYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXuXY1kUUN3ME20Mlg3QTV3IN88US=> M1X4NXNCVkeHUh?=
TC-YIK MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHnS2NKSzVyPUSuPVc6PDJizszN NYrMUZJ2W0GQR1XS
NCI-H1882 NUiyVZZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4KyNWlEPTB;NT6wNlAxOSEQvF2= MX\TRW5ITVJ?
MHH-CALL-2 Mni5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVO5e|dnUUN3ME21MlA2ODR{IN88US=> NI\LcplUSU6JRWK=
U-87-MG NIfac5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXMR2FKSzVyPUWuNFk1PjZizszN Mn;TV2FPT0WU
NCI-H1092 NVe4UHhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLuZmcyUUN3ME21MlI3PTV3IN88US=> MnTqV2FPT0WU
TE-441-T MnzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfLTWM2OD13LkK3PFIh|ryP NUTQcIhIW0GQR1XS
SK-MEL-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXLTWM2OD13LkK5NFQ1KM7:TR?= NUTjVXFbW0GQR1XS
EW-22 NEfjenJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;mbmlEPTB;NT6yPVQ3PiEQvF2= M{CzfHNCVkeHUh?=
MZ7-mel Ml3RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TBWmlEPTB;NT60NFY6OSEQvF2= MXzTRW5ITVJ?
LP-1 NEjSOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD13LkSxNlkyKM7:TR?= MY\TRW5ITVJ?
NCI-SNU-16 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTVwNkSwO|Qh|ryP MknGV2FPT0WU
LU-65 NHLGT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPqT5hKSzVyPUWuO|Y{PzNizszN MXXTRW5ITVJ?
CW-2 M2LKT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTVwOEW5OVkh|ryP MkDLV2FPT0WU
WSU-NHL MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTVwOUWxO|Qh|ryP NEXnN3NUSU6JRWK=
IST-MES1 M2TuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jMeGlEPTB;NT65OVQ1OyEQvF2= NYLKc3hzW0GQR1XS
U-266 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXqd5MyUUN3ME21Mlk5OjB{IN88US=> MYXTRW5ITVJ?
TALL-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTZwMUS2PFgh|ryP M1LqOHNCVkeHUh?=
Calu-6 NFLDdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XwUWlEPTB;Nj6xOVMyPiEQvF2= MnfpV2FPT0WU
MMAC-SF MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTZwMUi1OVYh|ryP MlfMV2FPT0WU
NCI-H82 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXr1c4RwUUN3ME22MlIxPDh7IN88US=> M3XnWnNCVkeHUh?=
RS4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRTZwMkW4PVch|ryP MoTpV2FPT0WU
SNU-C2B NV24OpZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrneIVxUUN3ME22MlQxQTZ7IN88US=> Mmj0V2FPT0WU
BOKU MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKxTWM2OD14LkS3OVk4KM7:TR?= MkTpV2FPT0WU
C8166 NGDhdVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPac4JrUUN3ME22MlU2QTF{IN88US=> MWLTRW5ITVJ?
D-247MG NXPDdGNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTdwMESzOFch|ryP NWjrbIh4W0GQR1XS
EW-18 Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\2emlEPTB;Nz6wO|I6OiEQvF2= NFflO|JUSU6JRWK=
KG-1 NH7FO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fkNGlEPTB;Nz62Nlc{QCEQvF2= NWi5XIlwW0GQR1XS
REH M4fNbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTdwNkixNFkh|ryP M1zTXHNCVkeHUh?=
U-698-M NXvQVXFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTdwOESzNVUh|ryP M2TtNXNCVkeHUh?=
KP-N-RT-BM-1 MlXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrPTWM2OD15LkmzNFI6KM7:TR?= NWHIV|RQW0GQR1XS
MS-1 NV7ITVlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTdwOU[wOFEh|ryP MlHZV2FPT0WU
SNU-C1 MnnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HFSGlEPTB;Nz65PFE6OiEQvF2= NEm0XI5USU6JRWK=
SK-MM-2 NGm4Z5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXmb5VKSzVyPUiuNlYxPjVizszN MoXZV2FPT0WU
LAN-6 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO1TWM2OD16LkOwNFAyKM7:TR?= Ml;qV2FPT0WU
NEC8 MlniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HVcmlEPTB;OD6zNFY6OSEQvF2= Mn7KV2FPT0WU
NCI-H1770 NX[3XHZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzC[4VKSzVyPUiuN|gxODJizszN NYWwTIRyW0GQR1XS
D-336MG M1L0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPzSpVKSzVyPUiuOFAyOTZizszN Ml7RV2FPT0WU
COLO-829 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEWzN|dKSzVyPUiuOFg5PzlizszN MljxV2FPT0WU
LS-513 NGrGO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLRdYhqUUN3ME24MlU6PTl7IN88US=> MmSxV2FPT0WU
YT MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\vSGFKSzVyPUiuOlI1OjdizszN NWrsXnVLW0GQR1XS
EW-24 NXm1W4UyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr0PXpKSzVyPUiuO|Y2PCEQvF2= M3XiTXNCVkeHUh?=
IST-SL1 MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTsTWM2OD16Lki2OVQ{KM7:TR?= NWLmT2cxW0GQR1XS
CA46 NWm4NXJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFP4eYlKSzVyPUiuPVUxQThizszN Mmf2V2FPT0WU
NCI-H1838 MmPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmX5TWM2OD16Lkm4OlAzKM7:TR?= MonwV2FPT0WU
NCI-H719 NFHEWoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXrNmhKSzVyPUmuNlUzPzlizszN Mkf0V2FPT0WU
HCE-T MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i0dGlEPTB;OT6zNFg2OSEQvF2= MkHFV2FPT0WU
A498 NF3oU45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTlwM{[xNlQh|ryP MWrTRW5ITVJ?
LB831-BLC NVXseWNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTlwN{[1NlEh|ryP M2n0XHNCVkeHUh?=
SKM-1 NHPLfmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTyPVhKSzVyPUmuPFU6PjNizszN MkiyV2FPT0WU
THP-1 NVi5VFdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HzbGlEPTB;OT65OlkyQCEQvF2= MVrTRW5ITVJ?
SHP-77 MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFyLkSwO{DPxE1? M3vXcXNCVkeHUh?=
EW-3 NYPaS2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjJdHdGUUN3ME2xNE43Ojh7IN88US=> M2OwVXNCVkeHUh?=
KY821 NHi4e3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS3TWM2OD1zMD63OlMh|ryP M1v4fHNCVkeHUh?=
NCI-SNU-1 NV;ENpRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTFzLkCyNVch|ryP M2PLN3NCVkeHUh?=
HCC2218 NGf3eZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3LTWM2OD1zMT6zPVg3KM7:TR?= MmqwV2FPT0WU
IM-9 NVv6cHlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFzLkWxNFYh|ryP MX3TRW5ITVJ?
NCI-H889 MmXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4n1bmlEPTB;MUGuOVMyOyEQvF2= MY\TRW5ITVJ?
HDLM-2 NVjhfJdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF{LkSxOVkh|ryP MkH5V2FPT0WU
LB2518-MEL MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTF{Lk[4NVUh|ryP MoXXV2FPT0WU
NCI-H23 NX;LNXlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF|LkK0NlUh|ryP MWDTRW5ITVJ?
NB17 MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTlTWM2OD1zMz60OVc6KM7:TR?= NYjBbZlDW0GQR1XS
NCI-H322M MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTF2LkSwOlgh|ryP NX:xOHdIW0GQR1XS
SUP-T1 M2fP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnwRlNKSzVyPUG0MlQyOyEQvF2= M1LVcXNCVkeHUh?=
ES3 NWH1XG1CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3HTWM2OD1zNT6wO|A{KM7:TR?= MYPTRW5ITVJ?
ES5 M{nuV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTF3LkC3PFch|ryP MmDvV2FPT0WU
NCI-H1650 MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fWVWlEPTB;MUWuOFk4QSEQvF2= M1rCZXNCVkeHUh?=
NCI-H226 M{DHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTaTWM2OD1zNT64O|Y5KM7:TR?= MXvTRW5ITVJ?
COR-L88 NVK0ZZFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7G[oRxUUN3ME2xOk4{OTRizszN NIrEUJRUSU6JRWK=
SCC-15 NVTPOphiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITMZ3RKSzVyPUG2MlM5PjlizszN MVrTRW5ITVJ?
GOTO MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT0O3pKSzVyPUG2MlQ4QTNizszN M4rab3NCVkeHUh?=
SIMA Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF4LkS4NFIh|ryP NIDZTHNUSU6JRWK=
NCI-H1299 NIq0OI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTF5LkG1PVEh|ryP MkLkV2FPT0WU
NCI-H1581 M4D0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTF5LkSyNVkh|ryP M1PrWHNCVkeHUh?=
MHH-NB-11 NGfEfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[xUJJKSzVyPUG3Mlk3QDNizszN M2nZcHNCVkeHUh?=
MFM-223 NELnWVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPhN4hKSzVyPUG4MlA2OzhizszN NGW4XolUSU6JRWK=
ES7 NGHPVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1j5O2lEPTB;MUiuOVQ{OSEQvF2= Mlr6V2FPT0WU
JVM-3 M4LCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zCUmlEPTB;MUiuO|E4KM7:TR?= MW\TRW5ITVJ?
RL NULCdI5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJyLkO4PEDPxE1? MoHQV2FPT0WU
EC-GI-10 M4LPV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmKzTWM2OD1{MT6yNFQyKM7:TR?= NVjXe29OW0GQR1XS
LNCaP-Clone-FGC NGixb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPFd3RKSzVyPUKxMlY4PjhizszN MUDTRW5ITVJ?
IMR-5 M2jS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWW3PJprUUN3ME2yNU45PDl2IN88US=> MmCzV2FPT0WU
KP-N-YS NWqxTmxHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nLO2lEPTB;MkGuPFc2KM7:TR?= NUDMVVlSW0GQR1XS
Mo-T NUL6dopyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPHVo1NUUN3ME2yNk4zOTh3IN88US=> MXzTRW5ITVJ?
NCI-H128 NGe4R21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPyXFFKSzVyPUKzMlU5PTNizszN NYjl[4xOW0GQR1XS
RH-1 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLVUHIzUUN3ME2yN{44QDZ4IN88US=> MXLTRW5ITVJ?
NCI-H2171 NFvFUWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH33c|hKSzVyPUK0MlI1QDVizszN NUmxb4l5W0GQR1XS
RPMI-8866 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fMTGlEPTB;Mk[uO|QzKM7:TR?= NF2y[FJUSU6JRWK=
SK-N-FI M4nmRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX65TGI1UUN3ME2yO{4{QDFzIN88US=> NWDUblJtW0GQR1XS
LOXIMVI M{TZOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTJ5LkiwOVEh|ryP M1\BRnNCVkeHUh?=
P31-FUJ MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7OXY5SUUN3ME2zNU42Ozd2IN88US=> MVPTRW5ITVJ?
KMS-12-PE NIX1VYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLpNmpHUUN3ME20PU42OzB{IN88US=> MY\TRW5ITVJ?

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
体内研究 在体内,Rapamycin 处理,特定阻断mTOR下游靶点,如p70S6K磷酸化和激活,和PHAS-1/4E-BP1导致的eIF4E抑制释放, 完全阻断跖肌重量和纤维尺寸的肥厚增高。[3] 短期Rapamycin处理,即使按最低剂量0.16 mg/kg处理, 强抑制p70S6K活性, 与提高的肿瘤细胞死亡和Eker肾脏肿瘤坏死相关。[4] Rapamycin作用于CT-26移植瘤模型,通过降低VEGF产量,及阻断VEGF诱导的内皮细胞信号,而抑制转移性肿瘤生长和血管新生。[5] Rapamycin每天按4 mg/kg剂量处理C6移植瘤,显著降低肿瘤生长,和肿瘤血管通透性。[7]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

mTOR激酶免疫印迹法测定:

HEK293细胞按每孔2-2.5×105个细胞接种在12孔板上,DMEM培养基上血清饥饿处理24小时。使用浓度不断增加的Rapamycin(0.05-50 nM)在 37oC下处理细胞15分钟。加入血清,终浓度为20%,在37oC下处理30分钟。细胞溶解,使用SDS-PAGE分离细胞裂解液。再溶解的蛋白转移到聚偏(二)氟乙烯膜上,使用抗p70 S6激酶Thr-389的磷酸化的一抗进行免疫印迹。使用ImageQuant 和KaleidaGraph分析数据。
细胞实验:

[6]

+ 展开
  • Cell lines: U87-MG, T98G, 和 U373-MG
  • Concentrations: 溶于DMSO,终浓度为~25 μM
  • Incubation Time: 72 小时
  • Method:

    使用不同浓度Rapamycin处理细胞72小时。为了测量细胞活力,通过胰蛋白酶化收集细胞,使用台酚蓝染色,计数每孔的存活细胞数。为了测定细胞周期, 使细胞胰蛋白酶化,与70%乙醇混合, 使用碘化丙啶染色。使用FACScan流式细胞仪和CellQuest软件分析样本DNA含量。为了测定凋亡, 细胞染色,通过末端脱氧核苷酸转移酶调节的dUTP缺口末端标记法(TUNEL)技术,使用一个ApopTag凋亡检测试剂盒对细胞进行染色。为了测定酸性囊泡细胞器(AVO)的进展,使用吖啶橙(1 μg/mL)对细胞进行染色15分钟,使用荧光显微镜检测。为了量化AVOs的进展,使用吖啶橙(1 μg/mL) 对细胞进行染色15分钟, 然后使用胰蛋白酶-EDTA使其从实验板上移除,最后使用FACScan流式细胞仪和CellQuest 软件分析。为了分析自噬过程,细胞和0.05 mM丹(磺)酰戊二胺(MDC)在37oC下温育10分钟,然后在荧光显微镜下观察。


    (Only for Reference)
动物实验:

[7]

+ 展开
  • Animal Models: 皮下接种表达VEGF-A的C6大鼠胶质瘤细胞的无胸腺Nu/Nu小鼠
  • Formulation: 溶于溶剂溶液(0.2% 羧甲基纤维素和0.25% Tween-80,溶于无菌水)
  • Dosages: ~4 mg/kg/day
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 914.18
化学式

C51H79NO13

CAS号 53123-88-9
储存条件 powder
in solvent
别名 AY 22989,NSC-2260804

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03433183 Recruiting Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT03933904 Recruiting Castleman Disease|Castleman''s Disease Multicentric University of Pennsylvania September 25 2019 Phase 2
NCT03972592 Recruiting Vascular Malformations|Lymphatic Malformation University Hospital Tours|University Hospital Angers June 5 2019 Phase 2
NCT03811717 Completed Skeletal Muscle Energetics Queen''s University|University of Waterloo January 14 2019 Not Applicable
NCT03765944 Completed Bioequivalence Study Nobelpharma December 5 2018 Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

相关mTOR产品

Tags: 购买Rapamycin (Sirolimus) | Rapamycin (Sirolimus)供应商 | 采购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)价格 | Rapamycin (Sirolimus)生产 | 订购Rapamycin (Sirolimus) | Rapamycin (Sirolimus)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID